[GetPortalCommentsPageByObjectIdResponse(id=521001, encodeId=8c38521001e8, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:三月七日投了一篇迷你综述,当天副主编评估稿件,四月四日就给了据稿,基本上都是些客套话,没有很多针对文章本身的评论,因此也很难根据这个据稿意见改进稿子。当初投这个杂志,看重的是迷你综述都是免费的,而且感觉上面的综述水平也一般,所以对据稿不是很理解。主编建议转投另一个Open Access的杂志,当然不会考虑了。唯一好的地方是这个杂志据稿确实快,没浪费太多的时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=404, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40ef1613356, createdName=CYCY, createdTime=Mon Apr 04 18:28:00 CST 2016, time=2016-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502347, encodeId=044550234ec5, content=这就是传说中催稿后的结果,very funny, <br> Dear Professor XXX, <br> <br> Thank you very much for submitting your manuscript to Basic & Clinical <br> <br> Pharmacology & Toxicology. <br> <br> Your manuscript has now been reviewed by two external experts in the <br> <br> field as well as by the editor. I regret to inform you that the <br> <br> consensus has been that your paper is not acceptable for publication. <br> <br> Please find enclosed copies of the reviewers? reports that I hope you <br> <br> find helpful. <br> I do hope that this adverse decision does not deter you from submitting <br> <br> future important findings to Basic & Clinical Pharmacology & Toxicology. <br> <br> Thank you, again, for considering Basic & Clinical Pharmacology & <br> <br> Toxicology for submitting your studies. <br> <br> <br> Yours sincerely <br> <br> Kim Br?sen, MD <br> <br> Review: <br> <br> Date of review:2014-04-12 <br> <br> Comments to authors: <br> <br> Dear Dr XXX <br> <br> Thank you very much for submitting your manuscript for publication in <br> <br> BCPT. <br> Because competition for our limited space is becoming increasingly keen, <br> <br> I must decline papers that might have been considered in the past. <br> <br> Guided by our constraints on space, two editors have concluded that your <br> <br> paper is likely to interest fewer readers than will others and that you <br> <br> and your readers will be better served if you submit the work elsewhere. <br> While we are always sorry to decline papers for this reason, we hope <br> <br> that you will accept this verdict in the constructive spirit in which it <br> <br> is offered. We hope that our prompt response will enable you to submit <br> <br> your manuscript to a specialty journal, which will probably welcome this <br> <br> account of your work. <br> <br> Thank you for allowing us to see it. <br> Sincerely, <br> <br> Jens Lykkesfeldt <br> <br> Professor, PhD, DSc <br> <br> Assoc. Editor, BCPT <br> <br> Review: <br> <br> Date of review:2014-04-13 <br> <br> Comments to authors: <br> <br> This paper has been evaluated by two editors <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=538, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=winner01072, createdTime=Mon Apr 14 17:35:00 CST 2014, time=2014-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502239, encodeId=56e65022394e, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享:Date submitted: 2013-12-18 <br> Decision date: 2014-03-24 <br> Decision: Accept with revision <br> <br> Date submitted: 2014-04-05(修改稿提交时间) <br> Decision date: 2014-04-08 <br> Decision: Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=389, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Apr 08 19:28:00 CST 2014, time=2014-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502182, encodeId=01ca502182b4, content=楼下的,Accept with revision意思是不是就是接受了啊? <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=420, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sun Apr 06 10:07:00 CST 2014, time=2014-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502181, encodeId=a49550218134, content=Accept with revision意思是一般就接受了呗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=628, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sun Apr 06 10:06:00 CST 2014, time=2014-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502176, encodeId=88a65021e645, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享:Date submitted: 2013-12-18 <br> Decision date: 2014-03-24 <br> Decision: Accept with revision, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=470, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sat Apr 05 13:04:00 CST 2014, time=2014-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502149, encodeId=fe7a50214911, content=接受率30%左右, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=413, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=winner01072, createdTime=Thu Apr 03 12:40:00 CST 2014, time=2014-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=501950, encodeId=97ec501950df, content=Reject but encourage resubmission <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=366, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sun Mar 23 12:01:00 CST 2014, time=2014-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=482158, encodeId=c2ff48215837, content=偏重的研究方向:毒理;, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=491, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=neuron2010, createdTime=Wed Jun 29 17:19:00 CST 2011, time=2011-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=474985, encodeId=10634e498563, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:超过6页需要收费, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=506, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da3636509, createdName=liyuanyuan418, createdTime=Wed Apr 20 19:12:00 CST 2011, time=2011-04-20, status=1, ipAttribution=)]
[GetPortalCommentsPageByObjectIdResponse(id=521001, encodeId=8c38521001e8, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:三月七日投了一篇迷你综述,当天副主编评估稿件,四月四日就给了据稿,基本上都是些客套话,没有很多针对文章本身的评论,因此也很难根据这个据稿意见改进稿子。当初投这个杂志,看重的是迷你综述都是免费的,而且感觉上面的综述水平也一般,所以对据稿不是很理解。主编建议转投另一个Open Access的杂志,当然不会考虑了。唯一好的地方是这个杂志据稿确实快,没浪费太多的时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=404, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40ef1613356, createdName=CYCY, createdTime=Mon Apr 04 18:28:00 CST 2016, time=2016-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502347, encodeId=044550234ec5, content=这就是传说中催稿后的结果,very funny, <br> Dear Professor XXX, <br> <br> Thank you very much for submitting your manuscript to Basic & Clinical <br> <br> Pharmacology & Toxicology. <br> <br> Your manuscript has now been reviewed by two external experts in the <br> <br> field as well as by the editor. I regret to inform you that the <br> <br> consensus has been that your paper is not acceptable for publication. <br> <br> Please find enclosed copies of the reviewers? reports that I hope you <br> <br> find helpful. <br> I do hope that this adverse decision does not deter you from submitting <br> <br> future important findings to Basic & Clinical Pharmacology & Toxicology. <br> <br> Thank you, again, for considering Basic & Clinical Pharmacology & <br> <br> Toxicology for submitting your studies. <br> <br> <br> Yours sincerely <br> <br> Kim Br?sen, MD <br> <br> Review: <br> <br> Date of review:2014-04-12 <br> <br> Comments to authors: <br> <br> Dear Dr XXX <br> <br> Thank you very much for submitting your manuscript for publication in <br> <br> BCPT. <br> Because competition for our limited space is becoming increasingly keen, <br> <br> I must decline papers that might have been considered in the past. <br> <br> Guided by our constraints on space, two editors have concluded that your <br> <br> paper is likely to interest fewer readers than will others and that you <br> <br> and your readers will be better served if you submit the work elsewhere. <br> While we are always sorry to decline papers for this reason, we hope <br> <br> that you will accept this verdict in the constructive spirit in which it <br> <br> is offered. We hope that our prompt response will enable you to submit <br> <br> your manuscript to a specialty journal, which will probably welcome this <br> <br> account of your work. <br> <br> Thank you for allowing us to see it. <br> Sincerely, <br> <br> Jens Lykkesfeldt <br> <br> Professor, PhD, DSc <br> <br> Assoc. Editor, BCPT <br> <br> Review: <br> <br> Date of review:2014-04-13 <br> <br> Comments to authors: <br> <br> This paper has been evaluated by two editors <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=538, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=winner01072, createdTime=Mon Apr 14 17:35:00 CST 2014, time=2014-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502239, encodeId=56e65022394e, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享:Date submitted: 2013-12-18 <br> Decision date: 2014-03-24 <br> Decision: Accept with revision <br> <br> Date submitted: 2014-04-05(修改稿提交时间) <br> Decision date: 2014-04-08 <br> Decision: Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=389, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Apr 08 19:28:00 CST 2014, time=2014-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502182, encodeId=01ca502182b4, content=楼下的,Accept with revision意思是不是就是接受了啊? <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=420, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sun Apr 06 10:07:00 CST 2014, time=2014-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502181, encodeId=a49550218134, content=Accept with revision意思是一般就接受了呗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=628, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sun Apr 06 10:06:00 CST 2014, time=2014-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502176, encodeId=88a65021e645, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享:Date submitted: 2013-12-18 <br> Decision date: 2014-03-24 <br> Decision: Accept with revision, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=470, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sat Apr 05 13:04:00 CST 2014, time=2014-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502149, encodeId=fe7a50214911, content=接受率30%左右, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=413, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=winner01072, createdTime=Thu Apr 03 12:40:00 CST 2014, time=2014-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=501950, encodeId=97ec501950df, content=Reject but encourage resubmission <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=366, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sun Mar 23 12:01:00 CST 2014, time=2014-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=482158, encodeId=c2ff48215837, content=偏重的研究方向:毒理;, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=491, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=neuron2010, createdTime=Wed Jun 29 17:19:00 CST 2011, time=2011-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=474985, encodeId=10634e498563, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:超过6页需要收费, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=506, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da3636509, createdName=liyuanyuan418, createdTime=Wed Apr 20 19:12:00 CST 2011, time=2011-04-20, status=1, ipAttribution=)]
[GetPortalCommentsPageByObjectIdResponse(id=521001, encodeId=8c38521001e8, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:三月七日投了一篇迷你综述,当天副主编评估稿件,四月四日就给了据稿,基本上都是些客套话,没有很多针对文章本身的评论,因此也很难根据这个据稿意见改进稿子。当初投这个杂志,看重的是迷你综述都是免费的,而且感觉上面的综述水平也一般,所以对据稿不是很理解。主编建议转投另一个Open Access的杂志,当然不会考虑了。唯一好的地方是这个杂志据稿确实快,没浪费太多的时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=404, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40ef1613356, createdName=CYCY, createdTime=Mon Apr 04 18:28:00 CST 2016, time=2016-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502347, encodeId=044550234ec5, content=这就是传说中催稿后的结果,very funny, <br> Dear Professor XXX, <br> <br> Thank you very much for submitting your manuscript to Basic & Clinical <br> <br> Pharmacology & Toxicology. <br> <br> Your manuscript has now been reviewed by two external experts in the <br> <br> field as well as by the editor. I regret to inform you that the <br> <br> consensus has been that your paper is not acceptable for publication. <br> <br> Please find enclosed copies of the reviewers? reports that I hope you <br> <br> find helpful. <br> I do hope that this adverse decision does not deter you from submitting <br> <br> future important findings to Basic & Clinical Pharmacology & Toxicology. <br> <br> Thank you, again, for considering Basic & Clinical Pharmacology & <br> <br> Toxicology for submitting your studies. <br> <br> <br> Yours sincerely <br> <br> Kim Br?sen, MD <br> <br> Review: <br> <br> Date of review:2014-04-12 <br> <br> Comments to authors: <br> <br> Dear Dr XXX <br> <br> Thank you very much for submitting your manuscript for publication in <br> <br> BCPT. <br> Because competition for our limited space is becoming increasingly keen, <br> <br> I must decline papers that might have been considered in the past. <br> <br> Guided by our constraints on space, two editors have concluded that your <br> <br> paper is likely to interest fewer readers than will others and that you <br> <br> and your readers will be better served if you submit the work elsewhere. <br> While we are always sorry to decline papers for this reason, we hope <br> <br> that you will accept this verdict in the constructive spirit in which it <br> <br> is offered. We hope that our prompt response will enable you to submit <br> <br> your manuscript to a specialty journal, which will probably welcome this <br> <br> account of your work. <br> <br> Thank you for allowing us to see it. <br> Sincerely, <br> <br> Jens Lykkesfeldt <br> <br> Professor, PhD, DSc <br> <br> Assoc. Editor, BCPT <br> <br> Review: <br> <br> Date of review:2014-04-13 <br> <br> Comments to authors: <br> <br> This paper has been evaluated by two editors <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=538, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=winner01072, createdTime=Mon Apr 14 17:35:00 CST 2014, time=2014-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502239, encodeId=56e65022394e, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享:Date submitted: 2013-12-18 <br> Decision date: 2014-03-24 <br> Decision: Accept with revision <br> <br> Date submitted: 2014-04-05(修改稿提交时间) <br> Decision date: 2014-04-08 <br> Decision: Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=389, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Apr 08 19:28:00 CST 2014, time=2014-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502182, encodeId=01ca502182b4, content=楼下的,Accept with revision意思是不是就是接受了啊? <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=420, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sun Apr 06 10:07:00 CST 2014, time=2014-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502181, encodeId=a49550218134, content=Accept with revision意思是一般就接受了呗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=628, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sun Apr 06 10:06:00 CST 2014, time=2014-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502176, encodeId=88a65021e645, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享:Date submitted: 2013-12-18 <br> Decision date: 2014-03-24 <br> Decision: Accept with revision, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=470, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sat Apr 05 13:04:00 CST 2014, time=2014-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502149, encodeId=fe7a50214911, content=接受率30%左右, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=413, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=winner01072, createdTime=Thu Apr 03 12:40:00 CST 2014, time=2014-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=501950, encodeId=97ec501950df, content=Reject but encourage resubmission <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=366, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sun Mar 23 12:01:00 CST 2014, time=2014-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=482158, encodeId=c2ff48215837, content=偏重的研究方向:毒理;, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=491, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=neuron2010, createdTime=Wed Jun 29 17:19:00 CST 2011, time=2011-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=474985, encodeId=10634e498563, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:超过6页需要收费, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=506, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da3636509, createdName=liyuanyuan418, createdTime=Wed Apr 20 19:12:00 CST 2011, time=2011-04-20, status=1, ipAttribution=)]
[GetPortalCommentsPageByObjectIdResponse(id=521001, encodeId=8c38521001e8, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:三月七日投了一篇迷你综述,当天副主编评估稿件,四月四日就给了据稿,基本上都是些客套话,没有很多针对文章本身的评论,因此也很难根据这个据稿意见改进稿子。当初投这个杂志,看重的是迷你综述都是免费的,而且感觉上面的综述水平也一般,所以对据稿不是很理解。主编建议转投另一个Open Access的杂志,当然不会考虑了。唯一好的地方是这个杂志据稿确实快,没浪费太多的时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=404, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40ef1613356, createdName=CYCY, createdTime=Mon Apr 04 18:28:00 CST 2016, time=2016-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502347, encodeId=044550234ec5, content=这就是传说中催稿后的结果,very funny, <br> Dear Professor XXX, <br> <br> Thank you very much for submitting your manuscript to Basic & Clinical <br> <br> Pharmacology & Toxicology. <br> <br> Your manuscript has now been reviewed by two external experts in the <br> <br> field as well as by the editor. I regret to inform you that the <br> <br> consensus has been that your paper is not acceptable for publication. <br> <br> Please find enclosed copies of the reviewers? reports that I hope you <br> <br> find helpful. <br> I do hope that this adverse decision does not deter you from submitting <br> <br> future important findings to Basic & Clinical Pharmacology & Toxicology. <br> <br> Thank you, again, for considering Basic & Clinical Pharmacology & <br> <br> Toxicology for submitting your studies. <br> <br> <br> Yours sincerely <br> <br> Kim Br?sen, MD <br> <br> Review: <br> <br> Date of review:2014-04-12 <br> <br> Comments to authors: <br> <br> Dear Dr XXX <br> <br> Thank you very much for submitting your manuscript for publication in <br> <br> BCPT. <br> Because competition for our limited space is becoming increasingly keen, <br> <br> I must decline papers that might have been considered in the past. <br> <br> Guided by our constraints on space, two editors have concluded that your <br> <br> paper is likely to interest fewer readers than will others and that you <br> <br> and your readers will be better served if you submit the work elsewhere. <br> While we are always sorry to decline papers for this reason, we hope <br> <br> that you will accept this verdict in the constructive spirit in which it <br> <br> is offered. We hope that our prompt response will enable you to submit <br> <br> your manuscript to a specialty journal, which will probably welcome this <br> <br> account of your work. <br> <br> Thank you for allowing us to see it. <br> Sincerely, <br> <br> Jens Lykkesfeldt <br> <br> Professor, PhD, DSc <br> <br> Assoc. Editor, BCPT <br> <br> Review: <br> <br> Date of review:2014-04-13 <br> <br> Comments to authors: <br> <br> This paper has been evaluated by two editors <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=538, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=winner01072, createdTime=Mon Apr 14 17:35:00 CST 2014, time=2014-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502239, encodeId=56e65022394e, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享:Date submitted: 2013-12-18 <br> Decision date: 2014-03-24 <br> Decision: Accept with revision <br> <br> Date submitted: 2014-04-05(修改稿提交时间) <br> Decision date: 2014-04-08 <br> Decision: Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=389, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Apr 08 19:28:00 CST 2014, time=2014-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502182, encodeId=01ca502182b4, content=楼下的,Accept with revision意思是不是就是接受了啊? <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=420, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sun Apr 06 10:07:00 CST 2014, time=2014-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502181, encodeId=a49550218134, content=Accept with revision意思是一般就接受了呗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=628, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sun Apr 06 10:06:00 CST 2014, time=2014-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502176, encodeId=88a65021e645, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享:Date submitted: 2013-12-18 <br> Decision date: 2014-03-24 <br> Decision: Accept with revision, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=470, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sat Apr 05 13:04:00 CST 2014, time=2014-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502149, encodeId=fe7a50214911, content=接受率30%左右, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=413, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=winner01072, createdTime=Thu Apr 03 12:40:00 CST 2014, time=2014-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=501950, encodeId=97ec501950df, content=Reject but encourage resubmission <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=366, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sun Mar 23 12:01:00 CST 2014, time=2014-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=482158, encodeId=c2ff48215837, content=偏重的研究方向:毒理;, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=491, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=neuron2010, createdTime=Wed Jun 29 17:19:00 CST 2011, time=2011-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=474985, encodeId=10634e498563, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:超过6页需要收费, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=506, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da3636509, createdName=liyuanyuan418, createdTime=Wed Apr 20 19:12:00 CST 2011, time=2011-04-20, status=1, ipAttribution=)]
[GetPortalCommentsPageByObjectIdResponse(id=521001, encodeId=8c38521001e8, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:三月七日投了一篇迷你综述,当天副主编评估稿件,四月四日就给了据稿,基本上都是些客套话,没有很多针对文章本身的评论,因此也很难根据这个据稿意见改进稿子。当初投这个杂志,看重的是迷你综述都是免费的,而且感觉上面的综述水平也一般,所以对据稿不是很理解。主编建议转投另一个Open Access的杂志,当然不会考虑了。唯一好的地方是这个杂志据稿确实快,没浪费太多的时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=404, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40ef1613356, createdName=CYCY, createdTime=Mon Apr 04 18:28:00 CST 2016, time=2016-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502347, encodeId=044550234ec5, content=这就是传说中催稿后的结果,very funny, <br> Dear Professor XXX, <br> <br> Thank you very much for submitting your manuscript to Basic & Clinical <br> <br> Pharmacology & Toxicology. <br> <br> Your manuscript has now been reviewed by two external experts in the <br> <br> field as well as by the editor. I regret to inform you that the <br> <br> consensus has been that your paper is not acceptable for publication. <br> <br> Please find enclosed copies of the reviewers? reports that I hope you <br> <br> find helpful. <br> I do hope that this adverse decision does not deter you from submitting <br> <br> future important findings to Basic & Clinical Pharmacology & Toxicology. <br> <br> Thank you, again, for considering Basic & Clinical Pharmacology & <br> <br> Toxicology for submitting your studies. <br> <br> <br> Yours sincerely <br> <br> Kim Br?sen, MD <br> <br> Review: <br> <br> Date of review:2014-04-12 <br> <br> Comments to authors: <br> <br> Dear Dr XXX <br> <br> Thank you very much for submitting your manuscript for publication in <br> <br> BCPT. <br> Because competition for our limited space is becoming increasingly keen, <br> <br> I must decline papers that might have been considered in the past. <br> <br> Guided by our constraints on space, two editors have concluded that your <br> <br> paper is likely to interest fewer readers than will others and that you <br> <br> and your readers will be better served if you submit the work elsewhere. <br> While we are always sorry to decline papers for this reason, we hope <br> <br> that you will accept this verdict in the constructive spirit in which it <br> <br> is offered. We hope that our prompt response will enable you to submit <br> <br> your manuscript to a specialty journal, which will probably welcome this <br> <br> account of your work. <br> <br> Thank you for allowing us to see it. <br> Sincerely, <br> <br> Jens Lykkesfeldt <br> <br> Professor, PhD, DSc <br> <br> Assoc. Editor, BCPT <br> <br> Review: <br> <br> Date of review:2014-04-13 <br> <br> Comments to authors: <br> <br> This paper has been evaluated by two editors <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=538, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=winner01072, createdTime=Mon Apr 14 17:35:00 CST 2014, time=2014-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502239, encodeId=56e65022394e, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享:Date submitted: 2013-12-18 <br> Decision date: 2014-03-24 <br> Decision: Accept with revision <br> <br> Date submitted: 2014-04-05(修改稿提交时间) <br> Decision date: 2014-04-08 <br> Decision: Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=389, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Apr 08 19:28:00 CST 2014, time=2014-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502182, encodeId=01ca502182b4, content=楼下的,Accept with revision意思是不是就是接受了啊? <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=420, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sun Apr 06 10:07:00 CST 2014, time=2014-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502181, encodeId=a49550218134, content=Accept with revision意思是一般就接受了呗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=628, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sun Apr 06 10:06:00 CST 2014, time=2014-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502176, encodeId=88a65021e645, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享:Date submitted: 2013-12-18 <br> Decision date: 2014-03-24 <br> Decision: Accept with revision, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=470, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sat Apr 05 13:04:00 CST 2014, time=2014-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502149, encodeId=fe7a50214911, content=接受率30%左右, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=413, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=winner01072, createdTime=Thu Apr 03 12:40:00 CST 2014, time=2014-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=501950, encodeId=97ec501950df, content=Reject but encourage resubmission <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=366, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sun Mar 23 12:01:00 CST 2014, time=2014-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=482158, encodeId=c2ff48215837, content=偏重的研究方向:毒理;, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=491, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=neuron2010, createdTime=Wed Jun 29 17:19:00 CST 2011, time=2011-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=474985, encodeId=10634e498563, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:超过6页需要收费, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=506, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da3636509, createdName=liyuanyuan418, createdTime=Wed Apr 20 19:12:00 CST 2011, time=2011-04-20, status=1, ipAttribution=)]
[GetPortalCommentsPageByObjectIdResponse(id=521001, encodeId=8c38521001e8, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:三月七日投了一篇迷你综述,当天副主编评估稿件,四月四日就给了据稿,基本上都是些客套话,没有很多针对文章本身的评论,因此也很难根据这个据稿意见改进稿子。当初投这个杂志,看重的是迷你综述都是免费的,而且感觉上面的综述水平也一般,所以对据稿不是很理解。主编建议转投另一个Open Access的杂志,当然不会考虑了。唯一好的地方是这个杂志据稿确实快,没浪费太多的时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=404, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40ef1613356, createdName=CYCY, createdTime=Mon Apr 04 18:28:00 CST 2016, time=2016-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502347, encodeId=044550234ec5, content=这就是传说中催稿后的结果,very funny, <br> Dear Professor XXX, <br> <br> Thank you very much for submitting your manuscript to Basic & Clinical <br> <br> Pharmacology & Toxicology. <br> <br> Your manuscript has now been reviewed by two external experts in the <br> <br> field as well as by the editor. I regret to inform you that the <br> <br> consensus has been that your paper is not acceptable for publication. <br> <br> Please find enclosed copies of the reviewers? reports that I hope you <br> <br> find helpful. <br> I do hope that this adverse decision does not deter you from submitting <br> <br> future important findings to Basic & Clinical Pharmacology & Toxicology. <br> <br> Thank you, again, for considering Basic & Clinical Pharmacology & <br> <br> Toxicology for submitting your studies. <br> <br> <br> Yours sincerely <br> <br> Kim Br?sen, MD <br> <br> Review: <br> <br> Date of review:2014-04-12 <br> <br> Comments to authors: <br> <br> Dear Dr XXX <br> <br> Thank you very much for submitting your manuscript for publication in <br> <br> BCPT. <br> Because competition for our limited space is becoming increasingly keen, <br> <br> I must decline papers that might have been considered in the past. <br> <br> Guided by our constraints on space, two editors have concluded that your <br> <br> paper is likely to interest fewer readers than will others and that you <br> <br> and your readers will be better served if you submit the work elsewhere. <br> While we are always sorry to decline papers for this reason, we hope <br> <br> that you will accept this verdict in the constructive spirit in which it <br> <br> is offered. We hope that our prompt response will enable you to submit <br> <br> your manuscript to a specialty journal, which will probably welcome this <br> <br> account of your work. <br> <br> Thank you for allowing us to see it. <br> Sincerely, <br> <br> Jens Lykkesfeldt <br> <br> Professor, PhD, DSc <br> <br> Assoc. Editor, BCPT <br> <br> Review: <br> <br> Date of review:2014-04-13 <br> <br> Comments to authors: <br> <br> This paper has been evaluated by two editors <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=538, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=winner01072, createdTime=Mon Apr 14 17:35:00 CST 2014, time=2014-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502239, encodeId=56e65022394e, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享:Date submitted: 2013-12-18 <br> Decision date: 2014-03-24 <br> Decision: Accept with revision <br> <br> Date submitted: 2014-04-05(修改稿提交时间) <br> Decision date: 2014-04-08 <br> Decision: Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=389, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Apr 08 19:28:00 CST 2014, time=2014-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502182, encodeId=01ca502182b4, content=楼下的,Accept with revision意思是不是就是接受了啊? <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=420, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sun Apr 06 10:07:00 CST 2014, time=2014-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502181, encodeId=a49550218134, content=Accept with revision意思是一般就接受了呗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=628, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sun Apr 06 10:06:00 CST 2014, time=2014-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502176, encodeId=88a65021e645, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享:Date submitted: 2013-12-18 <br> Decision date: 2014-03-24 <br> Decision: Accept with revision, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=470, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sat Apr 05 13:04:00 CST 2014, time=2014-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502149, encodeId=fe7a50214911, content=接受率30%左右, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=413, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=winner01072, createdTime=Thu Apr 03 12:40:00 CST 2014, time=2014-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=501950, encodeId=97ec501950df, content=Reject but encourage resubmission <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=366, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sun Mar 23 12:01:00 CST 2014, time=2014-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=482158, encodeId=c2ff48215837, content=偏重的研究方向:毒理;, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=491, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=neuron2010, createdTime=Wed Jun 29 17:19:00 CST 2011, time=2011-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=474985, encodeId=10634e498563, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:超过6页需要收费, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=506, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da3636509, createdName=liyuanyuan418, createdTime=Wed Apr 20 19:12:00 CST 2011, time=2011-04-20, status=1, ipAttribution=)]
[GetPortalCommentsPageByObjectIdResponse(id=521001, encodeId=8c38521001e8, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:三月七日投了一篇迷你综述,当天副主编评估稿件,四月四日就给了据稿,基本上都是些客套话,没有很多针对文章本身的评论,因此也很难根据这个据稿意见改进稿子。当初投这个杂志,看重的是迷你综述都是免费的,而且感觉上面的综述水平也一般,所以对据稿不是很理解。主编建议转投另一个Open Access的杂志,当然不会考虑了。唯一好的地方是这个杂志据稿确实快,没浪费太多的时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=404, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40ef1613356, createdName=CYCY, createdTime=Mon Apr 04 18:28:00 CST 2016, time=2016-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502347, encodeId=044550234ec5, content=这就是传说中催稿后的结果,very funny, <br> Dear Professor XXX, <br> <br> Thank you very much for submitting your manuscript to Basic & Clinical <br> <br> Pharmacology & Toxicology. <br> <br> Your manuscript has now been reviewed by two external experts in the <br> <br> field as well as by the editor. I regret to inform you that the <br> <br> consensus has been that your paper is not acceptable for publication. <br> <br> Please find enclosed copies of the reviewers? reports that I hope you <br> <br> find helpful. <br> I do hope that this adverse decision does not deter you from submitting <br> <br> future important findings to Basic & Clinical Pharmacology & Toxicology. <br> <br> Thank you, again, for considering Basic & Clinical Pharmacology & <br> <br> Toxicology for submitting your studies. <br> <br> <br> Yours sincerely <br> <br> Kim Br?sen, MD <br> <br> Review: <br> <br> Date of review:2014-04-12 <br> <br> Comments to authors: <br> <br> Dear Dr XXX <br> <br> Thank you very much for submitting your manuscript for publication in <br> <br> BCPT. <br> Because competition for our limited space is becoming increasingly keen, <br> <br> I must decline papers that might have been considered in the past. <br> <br> Guided by our constraints on space, two editors have concluded that your <br> <br> paper is likely to interest fewer readers than will others and that you <br> <br> and your readers will be better served if you submit the work elsewhere. <br> While we are always sorry to decline papers for this reason, we hope <br> <br> that you will accept this verdict in the constructive spirit in which it <br> <br> is offered. We hope that our prompt response will enable you to submit <br> <br> your manuscript to a specialty journal, which will probably welcome this <br> <br> account of your work. <br> <br> Thank you for allowing us to see it. <br> Sincerely, <br> <br> Jens Lykkesfeldt <br> <br> Professor, PhD, DSc <br> <br> Assoc. Editor, BCPT <br> <br> Review: <br> <br> Date of review:2014-04-13 <br> <br> Comments to authors: <br> <br> This paper has been evaluated by two editors <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=538, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=winner01072, createdTime=Mon Apr 14 17:35:00 CST 2014, time=2014-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502239, encodeId=56e65022394e, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享:Date submitted: 2013-12-18 <br> Decision date: 2014-03-24 <br> Decision: Accept with revision <br> <br> Date submitted: 2014-04-05(修改稿提交时间) <br> Decision date: 2014-04-08 <br> Decision: Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=389, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Apr 08 19:28:00 CST 2014, time=2014-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502182, encodeId=01ca502182b4, content=楼下的,Accept with revision意思是不是就是接受了啊? <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=420, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sun Apr 06 10:07:00 CST 2014, time=2014-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502181, encodeId=a49550218134, content=Accept with revision意思是一般就接受了呗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=628, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sun Apr 06 10:06:00 CST 2014, time=2014-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502176, encodeId=88a65021e645, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享:Date submitted: 2013-12-18 <br> Decision date: 2014-03-24 <br> Decision: Accept with revision, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=470, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sat Apr 05 13:04:00 CST 2014, time=2014-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502149, encodeId=fe7a50214911, content=接受率30%左右, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=413, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=winner01072, createdTime=Thu Apr 03 12:40:00 CST 2014, time=2014-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=501950, encodeId=97ec501950df, content=Reject but encourage resubmission <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=366, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sun Mar 23 12:01:00 CST 2014, time=2014-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=482158, encodeId=c2ff48215837, content=偏重的研究方向:毒理;, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=491, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=neuron2010, createdTime=Wed Jun 29 17:19:00 CST 2011, time=2011-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=474985, encodeId=10634e498563, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:超过6页需要收费, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=506, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da3636509, createdName=liyuanyuan418, createdTime=Wed Apr 20 19:12:00 CST 2011, time=2011-04-20, status=1, ipAttribution=)]
[GetPortalCommentsPageByObjectIdResponse(id=521001, encodeId=8c38521001e8, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:三月七日投了一篇迷你综述,当天副主编评估稿件,四月四日就给了据稿,基本上都是些客套话,没有很多针对文章本身的评论,因此也很难根据这个据稿意见改进稿子。当初投这个杂志,看重的是迷你综述都是免费的,而且感觉上面的综述水平也一般,所以对据稿不是很理解。主编建议转投另一个Open Access的杂志,当然不会考虑了。唯一好的地方是这个杂志据稿确实快,没浪费太多的时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=404, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40ef1613356, createdName=CYCY, createdTime=Mon Apr 04 18:28:00 CST 2016, time=2016-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502347, encodeId=044550234ec5, content=这就是传说中催稿后的结果,very funny, <br> Dear Professor XXX, <br> <br> Thank you very much for submitting your manuscript to Basic & Clinical <br> <br> Pharmacology & Toxicology. <br> <br> Your manuscript has now been reviewed by two external experts in the <br> <br> field as well as by the editor. I regret to inform you that the <br> <br> consensus has been that your paper is not acceptable for publication. <br> <br> Please find enclosed copies of the reviewers? reports that I hope you <br> <br> find helpful. <br> I do hope that this adverse decision does not deter you from submitting <br> <br> future important findings to Basic & Clinical Pharmacology & Toxicology. <br> <br> Thank you, again, for considering Basic & Clinical Pharmacology & <br> <br> Toxicology for submitting your studies. <br> <br> <br> Yours sincerely <br> <br> Kim Br?sen, MD <br> <br> Review: <br> <br> Date of review:2014-04-12 <br> <br> Comments to authors: <br> <br> Dear Dr XXX <br> <br> Thank you very much for submitting your manuscript for publication in <br> <br> BCPT. <br> Because competition for our limited space is becoming increasingly keen, <br> <br> I must decline papers that might have been considered in the past. <br> <br> Guided by our constraints on space, two editors have concluded that your <br> <br> paper is likely to interest fewer readers than will others and that you <br> <br> and your readers will be better served if you submit the work elsewhere. <br> While we are always sorry to decline papers for this reason, we hope <br> <br> that you will accept this verdict in the constructive spirit in which it <br> <br> is offered. We hope that our prompt response will enable you to submit <br> <br> your manuscript to a specialty journal, which will probably welcome this <br> <br> account of your work. <br> <br> Thank you for allowing us to see it. <br> Sincerely, <br> <br> Jens Lykkesfeldt <br> <br> Professor, PhD, DSc <br> <br> Assoc. Editor, BCPT <br> <br> Review: <br> <br> Date of review:2014-04-13 <br> <br> Comments to authors: <br> <br> This paper has been evaluated by two editors <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=538, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=winner01072, createdTime=Mon Apr 14 17:35:00 CST 2014, time=2014-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502239, encodeId=56e65022394e, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享:Date submitted: 2013-12-18 <br> Decision date: 2014-03-24 <br> Decision: Accept with revision <br> <br> Date submitted: 2014-04-05(修改稿提交时间) <br> Decision date: 2014-04-08 <br> Decision: Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=389, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Apr 08 19:28:00 CST 2014, time=2014-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502182, encodeId=01ca502182b4, content=楼下的,Accept with revision意思是不是就是接受了啊? <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=420, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sun Apr 06 10:07:00 CST 2014, time=2014-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502181, encodeId=a49550218134, content=Accept with revision意思是一般就接受了呗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=628, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sun Apr 06 10:06:00 CST 2014, time=2014-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502176, encodeId=88a65021e645, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享:Date submitted: 2013-12-18 <br> Decision date: 2014-03-24 <br> Decision: Accept with revision, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=470, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sat Apr 05 13:04:00 CST 2014, time=2014-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502149, encodeId=fe7a50214911, content=接受率30%左右, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=413, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=winner01072, createdTime=Thu Apr 03 12:40:00 CST 2014, time=2014-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=501950, encodeId=97ec501950df, content=Reject but encourage resubmission <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=366, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sun Mar 23 12:01:00 CST 2014, time=2014-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=482158, encodeId=c2ff48215837, content=偏重的研究方向:毒理;, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=491, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=neuron2010, createdTime=Wed Jun 29 17:19:00 CST 2011, time=2011-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=474985, encodeId=10634e498563, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:超过6页需要收费, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=506, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da3636509, createdName=liyuanyuan418, createdTime=Wed Apr 20 19:12:00 CST 2011, time=2011-04-20, status=1, ipAttribution=)]
[GetPortalCommentsPageByObjectIdResponse(id=521001, encodeId=8c38521001e8, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:三月七日投了一篇迷你综述,当天副主编评估稿件,四月四日就给了据稿,基本上都是些客套话,没有很多针对文章本身的评论,因此也很难根据这个据稿意见改进稿子。当初投这个杂志,看重的是迷你综述都是免费的,而且感觉上面的综述水平也一般,所以对据稿不是很理解。主编建议转投另一个Open Access的杂志,当然不会考虑了。唯一好的地方是这个杂志据稿确实快,没浪费太多的时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=404, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40ef1613356, createdName=CYCY, createdTime=Mon Apr 04 18:28:00 CST 2016, time=2016-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502347, encodeId=044550234ec5, content=这就是传说中催稿后的结果,very funny, <br> Dear Professor XXX, <br> <br> Thank you very much for submitting your manuscript to Basic & Clinical <br> <br> Pharmacology & Toxicology. <br> <br> Your manuscript has now been reviewed by two external experts in the <br> <br> field as well as by the editor. I regret to inform you that the <br> <br> consensus has been that your paper is not acceptable for publication. <br> <br> Please find enclosed copies of the reviewers? reports that I hope you <br> <br> find helpful. <br> I do hope that this adverse decision does not deter you from submitting <br> <br> future important findings to Basic & Clinical Pharmacology & Toxicology. <br> <br> Thank you, again, for considering Basic & Clinical Pharmacology & <br> <br> Toxicology for submitting your studies. <br> <br> <br> Yours sincerely <br> <br> Kim Br?sen, MD <br> <br> Review: <br> <br> Date of review:2014-04-12 <br> <br> Comments to authors: <br> <br> Dear Dr XXX <br> <br> Thank you very much for submitting your manuscript for publication in <br> <br> BCPT. <br> Because competition for our limited space is becoming increasingly keen, <br> <br> I must decline papers that might have been considered in the past. <br> <br> Guided by our constraints on space, two editors have concluded that your <br> <br> paper is likely to interest fewer readers than will others and that you <br> <br> and your readers will be better served if you submit the work elsewhere. <br> While we are always sorry to decline papers for this reason, we hope <br> <br> that you will accept this verdict in the constructive spirit in which it <br> <br> is offered. We hope that our prompt response will enable you to submit <br> <br> your manuscript to a specialty journal, which will probably welcome this <br> <br> account of your work. <br> <br> Thank you for allowing us to see it. <br> Sincerely, <br> <br> Jens Lykkesfeldt <br> <br> Professor, PhD, DSc <br> <br> Assoc. Editor, BCPT <br> <br> Review: <br> <br> Date of review:2014-04-13 <br> <br> Comments to authors: <br> <br> This paper has been evaluated by two editors <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=538, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=winner01072, createdTime=Mon Apr 14 17:35:00 CST 2014, time=2014-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502239, encodeId=56e65022394e, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享:Date submitted: 2013-12-18 <br> Decision date: 2014-03-24 <br> Decision: Accept with revision <br> <br> Date submitted: 2014-04-05(修改稿提交时间) <br> Decision date: 2014-04-08 <br> Decision: Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=389, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Apr 08 19:28:00 CST 2014, time=2014-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502182, encodeId=01ca502182b4, content=楼下的,Accept with revision意思是不是就是接受了啊? <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=420, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sun Apr 06 10:07:00 CST 2014, time=2014-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502181, encodeId=a49550218134, content=Accept with revision意思是一般就接受了呗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=628, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sun Apr 06 10:06:00 CST 2014, time=2014-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502176, encodeId=88a65021e645, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享:Date submitted: 2013-12-18 <br> Decision date: 2014-03-24 <br> Decision: Accept with revision, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=470, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sat Apr 05 13:04:00 CST 2014, time=2014-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502149, encodeId=fe7a50214911, content=接受率30%左右, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=413, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=winner01072, createdTime=Thu Apr 03 12:40:00 CST 2014, time=2014-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=501950, encodeId=97ec501950df, content=Reject but encourage resubmission <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=366, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sun Mar 23 12:01:00 CST 2014, time=2014-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=482158, encodeId=c2ff48215837, content=偏重的研究方向:毒理;, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=491, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=neuron2010, createdTime=Wed Jun 29 17:19:00 CST 2011, time=2011-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=474985, encodeId=10634e498563, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:超过6页需要收费, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=506, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da3636509, createdName=liyuanyuan418, createdTime=Wed Apr 20 19:12:00 CST 2011, time=2011-04-20, status=1, ipAttribution=)]
[GetPortalCommentsPageByObjectIdResponse(id=521001, encodeId=8c38521001e8, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:三月七日投了一篇迷你综述,当天副主编评估稿件,四月四日就给了据稿,基本上都是些客套话,没有很多针对文章本身的评论,因此也很难根据这个据稿意见改进稿子。当初投这个杂志,看重的是迷你综述都是免费的,而且感觉上面的综述水平也一般,所以对据稿不是很理解。主编建议转投另一个Open Access的杂志,当然不会考虑了。唯一好的地方是这个杂志据稿确实快,没浪费太多的时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=404, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40ef1613356, createdName=CYCY, createdTime=Mon Apr 04 18:28:00 CST 2016, time=2016-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502347, encodeId=044550234ec5, content=这就是传说中催稿后的结果,very funny, <br> Dear Professor XXX, <br> <br> Thank you very much for submitting your manuscript to Basic & Clinical <br> <br> Pharmacology & Toxicology. <br> <br> Your manuscript has now been reviewed by two external experts in the <br> <br> field as well as by the editor. I regret to inform you that the <br> <br> consensus has been that your paper is not acceptable for publication. <br> <br> Please find enclosed copies of the reviewers? reports that I hope you <br> <br> find helpful. <br> I do hope that this adverse decision does not deter you from submitting <br> <br> future important findings to Basic & Clinical Pharmacology & Toxicology. <br> <br> Thank you, again, for considering Basic & Clinical Pharmacology & <br> <br> Toxicology for submitting your studies. <br> <br> <br> Yours sincerely <br> <br> Kim Br?sen, MD <br> <br> Review: <br> <br> Date of review:2014-04-12 <br> <br> Comments to authors: <br> <br> Dear Dr XXX <br> <br> Thank you very much for submitting your manuscript for publication in <br> <br> BCPT. <br> Because competition for our limited space is becoming increasingly keen, <br> <br> I must decline papers that might have been considered in the past. <br> <br> Guided by our constraints on space, two editors have concluded that your <br> <br> paper is likely to interest fewer readers than will others and that you <br> <br> and your readers will be better served if you submit the work elsewhere. <br> While we are always sorry to decline papers for this reason, we hope <br> <br> that you will accept this verdict in the constructive spirit in which it <br> <br> is offered. We hope that our prompt response will enable you to submit <br> <br> your manuscript to a specialty journal, which will probably welcome this <br> <br> account of your work. <br> <br> Thank you for allowing us to see it. <br> Sincerely, <br> <br> Jens Lykkesfeldt <br> <br> Professor, PhD, DSc <br> <br> Assoc. Editor, BCPT <br> <br> Review: <br> <br> Date of review:2014-04-13 <br> <br> Comments to authors: <br> <br> This paper has been evaluated by two editors <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=538, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=winner01072, createdTime=Mon Apr 14 17:35:00 CST 2014, time=2014-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502239, encodeId=56e65022394e, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享:Date submitted: 2013-12-18 <br> Decision date: 2014-03-24 <br> Decision: Accept with revision <br> <br> Date submitted: 2014-04-05(修改稿提交时间) <br> Decision date: 2014-04-08 <br> Decision: Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=389, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Apr 08 19:28:00 CST 2014, time=2014-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502182, encodeId=01ca502182b4, content=楼下的,Accept with revision意思是不是就是接受了啊? <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=420, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sun Apr 06 10:07:00 CST 2014, time=2014-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502181, encodeId=a49550218134, content=Accept with revision意思是一般就接受了呗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=628, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sun Apr 06 10:06:00 CST 2014, time=2014-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502176, encodeId=88a65021e645, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享:Date submitted: 2013-12-18 <br> Decision date: 2014-03-24 <br> Decision: Accept with revision, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=470, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sat Apr 05 13:04:00 CST 2014, time=2014-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502149, encodeId=fe7a50214911, content=接受率30%左右, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=413, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=winner01072, createdTime=Thu Apr 03 12:40:00 CST 2014, time=2014-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=501950, encodeId=97ec501950df, content=Reject but encourage resubmission <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=366, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sun Mar 23 12:01:00 CST 2014, time=2014-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=482158, encodeId=c2ff48215837, content=偏重的研究方向:毒理;, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=491, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=neuron2010, createdTime=Wed Jun 29 17:19:00 CST 2011, time=2011-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=474985, encodeId=10634e498563, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享:超过6页需要收费, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=506, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da3636509, createdName=liyuanyuan418, createdTime=Wed Apr 20 19:12:00 CST 2011, time=2011-04-20, status=1, ipAttribution=)]
审稿速度:1.0 | 投稿命中率:50.0
经验分享:三月七日投了一篇迷你综述,当天副主编评估稿件,四月四日就给了据稿,基本上都是些客套话,没有很多针对文章本身的评论,因此也很难根据这个据稿意见改进稿子。当初投这个杂志,看重的是迷你综述都是免费的,而且感觉上面的综述水平也一般,所以对据稿不是很理解。主编建议转投另一个Open Access的杂志,当然不会考虑了。唯一好的地方是这个杂志据稿确实快,没浪费太多的时间
404
这就是传说中催稿后的结果,very funny,
Dear Professor XXX,
Thank you very much for submitting your manuscript to Basic & Clinical
Pharmacology & Toxicology.
Your manuscript has now been reviewed by two external experts in the
field as well as by the editor. I regret to inform you that the
consensus has been that your paper is not acceptable for publication.
Please find enclosed copies of the reviewers? reports that I hope you
find helpful.
I do hope that this adverse decision does not deter you from submitting
future important findings to Basic & Clinical Pharmacology & Toxicology.
Thank you, again, for considering Basic & Clinical Pharmacology &
Toxicology for submitting your studies.
Yours sincerely
Kim Br?sen, MD
Review:
Date of review:2014-04-12
Comments to authors:
Dear Dr XXX
Thank you very much for submitting your manuscript for publication in
BCPT.
Because competition for our limited space is becoming increasingly keen,
I must decline papers that might have been considered in the past.
Guided by our constraints on space, two editors have concluded that your
paper is likely to interest fewer readers than will others and that you
and your readers will be better served if you submit the work elsewhere.
While we are always sorry to decline papers for this reason, we hope
that you will accept this verdict in the constructive spirit in which it
is offered. We hope that our prompt response will enable you to submit
your manuscript to a specialty journal, which will probably welcome this
account of your work.
Thank you for allowing us to see it.
Sincerely,
Jens Lykkesfeldt
Professor, PhD, DSc
Assoc. Editor, BCPT
Review:
Date of review:2014-04-13
Comments to authors:
This paper has been evaluated by two editors
538
审稿速度:6.0 | 投稿命中率:50.0
经验分享:Date submitted: 2013-12-18
Decision date: 2014-03-24
Decision: Accept with revision
Date submitted: 2014-04-05(修改稿提交时间)
Decision date: 2014-04-08
Decision: Accept
389
楼下的,Accept with revision意思是不是就是接受了啊?
420
Accept with revision意思是一般就接受了呗?
628
审稿速度:6.0 | 投稿命中率:50.0
经验分享:Date submitted: 2013-12-18
Decision date: 2014-03-24
Decision: Accept with revision
470
接受率30%左右
413
Reject but encourage resubmission
366
偏重的研究方向:毒理;
491
审稿速度:1.0 | 投稿命中率:50.0
经验分享:超过6页需要收费
506